WFDC2 and neoplasm: Thus, harmonization between the different devices should be a pillar for the appropriate clinical use of tumor markers, especially in the case of HE4, since the different threshold of its cut-off in discriminating between benign and malignant ovarian masses is, to date, a very controversial issue [24].